{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T23:10:58Z","timestamp":1782774658405,"version":"3.54.5"},"reference-count":17,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2026,2,1]]},"DOI":"10.1001\/jamaoncol.2025.5061","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T16:30:47Z","timestamp":1764865847000},"page":"143","source":"Crossref","is-referenced-by-count":1,"title":["Tailored COX-2 Inhibition for Precision Adjuvant Therapy of Localized Metastatic Colon Cancer"],"prefix":"10.1001","volume":"12","author":[{"given":"David A.","family":"Drew","sequence":"first","affiliation":[{"name":"Clinical & Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston"},{"name":"Division of Gastroenterology, Massachusetts of General Hospital and Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip E.","family":"Castle","sequence":"additional","affiliation":[{"name":"Divisions of Cancer Prevention and Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health\/Department of Health and Human Services, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"13","key":"ced250015r1","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1001\/jama.2021.2454","article-title":"Effect of celecoxib vs placebo added to standard adjuvant therapy on disease-free survival among patients with stage III colon cancer: the CALGB\/SWOG 80702 (Alliance) randomized clinical trial.","volume":"325","author":"Meyerhardt","year":"2021","journal-title":"JAMA"},{"issue":"24","key":"ced250015r2","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1200\/JCO.23.01680","article-title":"Improved survival with adjuvant cyclooxygenase 2 inhibition in PIK3CA-activated stage III colon cancer: CALGB\/SWOG 80702 (Alliance).","volume":"42","author":"Nowak","year":"2024","journal-title":"J Clin Oncol"},{"issue":"17","key":"ced250015r3","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1056\/NEJMoa1207756","article-title":"Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival.","volume":"367","author":"Liao","year":"2012","journal-title":"N Engl J Med"},{"issue":"34","key":"ced250015r4","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1200\/JCO.2013.50.0322","article-title":"Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.","volume":"31","author":"Domingo","year":"2013","journal-title":"J Clin Oncol"},{"issue":"30","key":"ced250015r5","doi-asserted-by":"publisher","first-page":"4575","DOI":"10.1200\/JCO.2010.29.6244","article-title":"Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial.","volume":"28","author":"Midgley","year":"2010","journal-title":"J Clin Oncol"},{"issue":"11","key":"ced250015r6","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1056\/NEJMoa2504650","article-title":"Low-dose aspirin for PI3K-altered localized colorectal cancer.","volume":"393","author":"Martling","year":"2025","journal-title":"N Engl J Med"},{"issue":"15","key":"ced250015r7","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1158\/1078-0432.CCR-24-4048","article-title":"Adjuvant aspirin treatment in PIK3CA-mutated colon cancer patients: the SAKK 41\/13 prospective randomized placebo-controlled double-blind trial.","volume":"31","author":"G\u00fcller","year":"2025","journal-title":"Clin Cancer Res"},{"key":"ced250015r8","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.5144","article-title":"Predictive role of circulating tumor DNA in stage III colon cancer treated with celecoxib: a post hoc analysis of the CALGB (Alliance)\/SWOG 80702 phase 3 randomized clinical trial.","author":"Zhang","journal-title":"JAMA Oncol"},{"issue":"8060","key":"ced250015r9","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/s41586-025-08626-7","article-title":"Aspirin prevents metastasis by limiting platelet TXA2 suppression of T cell immunity.","volume":"640","author":"Yang","year":"2025","journal-title":"Nature"},{"issue":"10","key":"ced250015r10","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1158\/1940-6207.CAPR-20-0216","article-title":"Effect of low-dose and standard-dose aspirin on PGE2 biosynthesis among individuals with colorectal adenomas: a randomized clinical trial.","volume":"13","author":"Drew","year":"2020","journal-title":"Cancer Prev Res (Phila)"},{"key":"ced250015r11","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1186\/s12885-016-2466-z","article-title":"The eicosanoids leukotriene D4 and prostaglandin E2 promote the tumorigenicity of colon cancer-initiating cells in a xenograft mouse model.","volume":"16","author":"Bellamkonda","year":"2016","journal-title":"BMC Cancer"},{"issue":"7","key":"ced250015r12","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1172\/JCI97953","article-title":"Role of prostanoids in gastrointestinal cancer.","volume":"128","author":"Wang","year":"2018","journal-title":"J Clin Invest"},{"issue":"9","key":"ced250015r13","doi-asserted-by":"publisher","first-page":"3606","DOI":"10.1172\/JCI81423","article-title":"Mucosally transplanted mesenchymal stem cells stimulate intestinal healing by promoting angiogenesis.","volume":"125","author":"Manieri","year":"2015","journal-title":"J Clin Invest"},{"issue":"8","key":"ced250015r15","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1158\/1940-6207.CAPR-10-0403","article-title":"C-reactive protein and risk of colorectal adenoma according to celecoxib treatment.","volume":"4","author":"Chan","year":"2011","journal-title":"Cancer Prev Res (Phila)"},{"issue":"9","key":"ced250015r16","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1056\/NEJMoa061355","article-title":"Celecoxib for the prevention of sporadic colorectal adenomas.","volume":"355","author":"Bertagnolli","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"ced250015r17","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMoa061652","article-title":"Celecoxib for the prevention of colorectal adenomatous polyps.","volume":"355","author":"Arber","year":"2006","journal-title":"N Engl J Med"},{"key":"ced250015r14","volume-title":"Medical Genetics Summaries","author":"Dean","year":"2012"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2842597\/jamaoncology_drew_2025_ed_250015_1771446083.2075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T16:01:05Z","timestamp":1771516865000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2842597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2025.5061","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,1]]}}}